Friedenthal Financial Purchases Shares of 9,152 Gilead Sciences, Inc. $GILD

Key Points

• Friedenthal Financial has acquired 9,152 shares of Gilead Sciences, Inc., valued at approximately $1,015,000, as reported in its recent SEC filing.
• Gilead Sciences reported $2.01 earnings per share for the last quarter, surpassing analysts' expectations of $1.96, with revenue of $7.08 billion.
• Insiders at Gilead Sciences sold a total of 82,000 shares valued at over $9.4 million in the last three months, indicating potential shifts in confidence among management.

Friedenthal Financial purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 9,152 shares of the biopharmaceutical company's stock, valued at approximately $1,015,000.

Other large investors have also recently added to or reduced their stakes in the company. One Wealth Advisors LLC raised its holdings in Gilead Sciences by 34.8% in the 2nd quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company's stock valued at $1,016,000 after acquiring an additional 2,364 shares in the last quarter. Ariel Investments LLC raised its holdings in Gilead Sciences by 7.7% in the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company's stock valued at $48,229,000 after acquiring an additional 30,630 shares in the last quarter. Golden State Wealth Management LLC grew its stake in shares of Gilead Sciences by 14.5% in the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock valued at $97,000 after purchasing an additional 109 shares during the period. Covea Finance grew its stake in shares of Gilead Sciences by 69.5% in the 2nd quarter. Covea Finance now owns 51,700 shares of the biopharmaceutical company's stock valued at $5,732,000 after purchasing an additional 21,200 shares during the period. Finally, Swedbank AB grew its stake in shares of Gilead Sciences by 0.8% in the 1st quarter. Swedbank AB now owns 2,118,632 shares of the biopharmaceutical company's stock valued at $237,393,000 after purchasing an additional 16,663 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $340,710.00. Following the transaction, the insider owned 113,193 shares of the company's stock, valued at approximately $12,855,329.01. The trade was a 2.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $283,925.00. Following the completion of the transaction, the chief financial officer directly owned 159,555 shares in the company, valued at $18,120,661.35. This trade represents a 1.54% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock valued at $9,402,130 over the last three months. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $116.78 on Wednesday. The firm has a fifty day moving average price of $114.41 and a 200-day moving average price of $110.06. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The stock has a market cap of $144.90 billion, a PE ratio of 23.26, a price-to-earnings-growth ratio of 0.77 and a beta of 0.34. Gilead Sciences, Inc. has a 1 year low of $84.17 and a 1 year high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the prior year, the company posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were paid a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. Gilead Sciences's dividend payout ratio is 62.95%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on GILD shares. UBS Group upped their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research note on Friday, August 8th. Dbs Bank upgraded Gilead Sciences to a "moderate buy" rating in a research note on Friday, September 5th. Daiwa Capital Markets upgraded Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective on the stock in a research note on Tuesday, August 19th. Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and upped their price objective for the company from $108.00 to $127.00 in a research note on Friday, August 8th. Finally, Weiss Ratings reiterated a "buy (b)" rating on shares of Gilead Sciences in a research note on Saturday, September 27th. Three research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and an average target price of $117.17.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.